Pharmacologic strategies for the correction of amblyopia


visual acuity

How to Cite

Paliz Sanchez, C. D. R., Delgado Cruz, M. V., & Flores Valero, M. F. (2024). Pharmacologic strategies for the correction of amblyopia. Universidad Ciencia Y Tecnología, 28(123), 82-93.


Amblyopia, also known as lazy eye, is a decrease in visual acuity in one or both eyes due to abnormal visual development during childhood. It is established during the first years of life by inadequate visual stimulation secondary to various causes. An early diagnosis is needed to apply any existing treatments on time. Among them, is a strategy based on the application of drugs. This study aims to present the state of the issue of pharmacological strategies for correcting amblyopia in children from 0 to 5 years. For this purpose, bibliographic and documentary archiving was carried out with academic material and scientific articles. It was found that the main pharmacological treatments of amblyopia use atropine and levodopa.


[1] A. Jacobson, C. Besirli y B. Bohnsack, «Outcomes of Baerveldt Glaucoma Drainage Devices in Pediatric Eyes.,» Journal of Glaucoma, vol. 31, nº 6, pp. 468-477, 2021.
[2] Academia Americana de Oftalmología , Oftalmología pediátrica y estrabismo, Madrid: Elsevier, 2008.
[3] V. Kattouf, «Options in Amblyopia,» de Visual development, diagnosis and treatment of the pediatric patient, Philadelphia, Lippinkot Williams & Willkins, 2006, pp. 382-392.
[4] J. Amaya, «Una opción farmacológica para el tratamiento de la ambliopía: levodopa,» Andina Visual, vol. 8, nº 13, pp. 6-15, 2013.
[5] M. Negrete, «Abliopía y plasticidad sensorial,» Universitat Politécnica de Catalunya, Terrassa, 2020.
[6] L. Basilio, «Principales factores de riesgo que condicionan ambliopía en niños de 6 a 14 años en el centro optómetra en cercado de Lima entre los años 2015 A 2018,» Universidad Ricardo Palma, Lima, 2021.
[7] B. Fortune y D. Hood, «Conventional pattern reversal VEPs are not equivalent to summed multifocal VEP,» Investigative Ophthalmology & Visual Sciences, vol. 44, nº 1, pp. 1364-1375, 2003.
[8] L. Molina, «Ambliopía: oclusión o penalización: nuevas perspectivas de tratamiento basadas en la evidencia,» Universitat Politécnica de Catalunya, Barcelona, 2021.
[9] A. N. L. Vagge, «Compliance with the prescribed occlusion treatment for Amblyopia,» Current Opinion Ophthalmol. , vol. 28, nº 5, pp. 454-459, 2017.
[10] E. Suttle, «Active treatments for amblyopia,» Clinical and Experimental Optometry, vol. 93, nº 5, pp. 297-299, 2010.
[11] I. Goncalves, «Blefaroptosis congénita y ambliopía en niña de 10 años de edad,» Universidad Técnica de Babahoyo, Babahoyo, 2017.
[12] F. Rowe, Clinical Orthoptics, USA: Willie Blackwell, 2012.
[13] M. Alcántara, «Estrabismo.,» Pediatria Integral, vol. 9, nº 6, pp. 431-446, 2005.
[14] L. Leguire y et al, «levodopa/ carbidopa for childhood amblyopia,» Investigation Ophthalmology Vision Science, vol. 34, nº 11, pp. 3090-3095, 2013.
[15] K. Mohan, V. Dhankar y A. Sharma, «Visual acuities after levodopa administration in amblyopia.,» Pediatr Ophthalmol Strabismus., vol. 38, nº 2, pp. 96-97, 2001.
[16] S. Dadeya, P. Vats y K. Malik, «Levodopa/ carbidopa in the treatment of amblyopia.,» Pediatric Ophthalmology Strabismus., vol. 46, nº 2, pp. 87-90, 2009.
[17] E. Procianoy, L. Procianoy y P. F, «Resultados do tratamento da ambliopia com levodopa combinada à oclusão.,» Arq. Brasil Oftalmology, vol. 67, nº 5, 2004.
[18] C. E. J. Pérez, «Tratamiento de la ambliopía basado en evidencia,» Unidad de Oftalmología Infantil. H.R.U. de Malaga, Malaga, 2021.
[19] E. Gaier y D. Hunter, «Advances in Amblyopia Treatment: Paradigm Shifts and Future Directions.,» International Ophthalmology Clinics., vol. 57, nº 4, pp. 117-128, 2017.
[20] A. Finlay, «Binocular vision disorders: Clinical investigation, diagnosis and management,» de Paediatric Optometry., United Kingdom, Optician, 2004, pp. 46-47.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.


Download data is not yet available.